局部晚期宫颈癌放化疗联合磁共振引导自适应近距离放疗后的总体严重发病率:EMBRACE-I研究结果
EMBRACE-I前瞻性研究纳入1416例局部晚期宫颈癌患者,接受放化疗联合磁共振引导自适应近距离放疗,1251例有晚期发病率随访数据。5年≥3级胃肠、泌尿、阴道和瘘的粗发生率分别为8.5%、6.8%、5.7%和3.2%,所有≥3级终点汇总为26.6%。作者结论认为胃肠、阴道发病率和瘘的结果优于标准X线片引导近距离放疗的已发表文献。
要点
- 5年≥3级胃肠、泌尿、阴道和瘘的粗发生率分别为8.5%、6.8%、5.7%和3.2%。
- 5年所有≥3级终点汇总的粗发生率为26.6%(95%CI 23.8%-29.6%)。
- 13例治疗相关死亡,其中8例与胃肠发病率相关。
核心结论
- 作者结论认为EMBRACE-I研究的晚期发病率结果在胃肠发病率、阴道发病率和瘘方面优于标准X线片引导近距离放疗的已发表文献。
- 严重晚期发病率按单个终点和器官类别有限,但跨器官和所有终点汇总时相当可观。
研究设计与样本
- 前瞻性EMBRACE-I研究于2008年至2015年纳入1416例局部晚期宫颈癌患者。
- 患者接受放化疗联合磁共振图像引导自适应近距离放疗。
- 发病率采用不良事件通用术语标准3.0版评估,第1年每3个月、第2和第3年每6个月、此后每年评估,1251例有晚期发病率随访数据。
- 发病率事件(3-5级)以随访期间最高级别汇总(粗发生率)及3年和5年生存估计表示。
- 为与标准X线片引导近距离放疗的已发表文献比较,EMBRACE-I研究的不良事件通用术语标准评分被回顾性转换为放射治疗肿瘤学组和欧洲癌症研究与治疗组织的对应评分。
主要发现
- 270例患者共发生534起严重事件,其中429起为3级事件,105起为4级事件。
- 5年≥3级胃肠、泌尿、阴道和瘘事件的生存估计分别为8.5%(95%CI 6.9%-10.6%)、6.8%(95%CI 5.4%-8.6%)、5.7%(95%CI 4.3%-7.6%)和3.2%(95%CI 2.2%-4.5%)。
- 5年器官相关事件(胃肠、泌尿、阴道或瘘)的生存估计为18.4%(95%CI 16.0%-21.2%)。
- 5年汇总所有≥3级终点(胃肠、泌尿、阴道、瘘和非胃肠/泌尿/阴道)的生存估计为26.6%(95%CI 23.8%-29.6%)。
- 13例患者发生治疗相关死亡,其中8例与胃肠发病率相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate overall severe late morbidity (grade ≥3) in patients with locally advanced cervical cancer treated with chemo-radiation therapy and magnetic resonance image guided adaptive brachytherapy within the prospective EMBRACE-I study, and to compare the results with published literature after standard radiograph based brachytherapy (BT). METHODS AND MATERIALS: From 2008 to 2015 the EMBRACE-I study enrolled 1416 patients. Morbidity was assessed (Common Terminology Criteria for Adverse Events version 3.0) every 3 months the 1st year, every 6 months the second and third year, and yearly thereafter and 1251 patients had available follow-up on late morbidity. Morbidity events (grade 3-5) were summarized as the maximum grade during follow-up (crude incidence rates) and actuarial estimates at 3 and 5 years. To compare with the published literature on standard radiograph based BT, Common Terminology Criteria for Adverse Events scores from the EMBRACE-I study were retrospectively converted into a corresponding score in the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer system. RESULTS: In total, 534 severe events occurred in 270 patients; 429 events were grade 3 and 105 were grade 4 events. Actuarial estimates for grade ≥3 gastrointestinal (GI), genitourinary (GU), vaginal and fistula events at 5 years were 8.5% (95% confidence interval [CI], 6.9%-10.6%), 6.8% (95% CI, 5.4%-8.6%), 5.7% (95% CI, 4.3%-7.6%), and 3.2% (95% CI, 2.2%-4.5%), respectively. The 5-year actuarial estimate for organ-related events (GI, GU, vaginal, or fistula) was 18.4% (95% CI, 16.0%-21.2%). The 5-year actuarial estimate when aggregating all G≥3 endpoints (GI, GU, vaginal, fistulas, and non-GI/GU/vaginal) was 26.6% (95% CI, 23.8%-29.6%). Thirteen patients had a treatment-related death, 8 of which were associated with GI morbidity. CONCLUSIONS: This report assesses severe morbidity from the largest prospective study on chemo-radiation therapy and image guided adaptive brachytherapy for locally advanced cervical cancer to date. Severe late morbidity was limited per endpoint and organ category, but considerable when aggregated across organs and all endpoints. The late morbidity results in the EMBRACE-I study compare favorably with published literature on standard radiograph based BT for GI morbidity, vaginal morbidity, and fistulas.
引用
- Vittrup AS, Kirchheiner K, Pötter R, et al. Overall Severe Morbidity After Chemo-Radiation Therapy and Magnetic Resonance Imaging-Guided Adaptive Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study. Int J Radiat Oncol Biol Phys. 2023. PMID: 36641039. doi:10.1016/j.ijrobp.2023.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。